Helpline: 0808 800 0303

Latest research projects

Vital new projects are getting underway in 2011 which will bring us closer to a cure for Parkinson's.

These exciting new studies focus on why nerve cells die in Parkinson's, and pioneering new treatments to improve the lives of people with the condition.

Studying nicotine's potential to treat Parkinson's

  • Dr Stephanie CraggDr Stephanie Cragg, University of Oxford
  • £142,451 over 2 years
  • Start date: tbc
  • Project grant: G-1103

Stephanie's research has shown that nicotine affects how nerve cells release dopamine. Her new project will explore how nicotine boosts dopamine release, and will hopefully lead to new treatments for people with Parkinson's.

Studying nicotine's potential to treat Parkinson's - research project summary (PDF, 170KB)


Understanding the role of the Fbxo7 gene in Parkinson's

  • Professor Dario AlessiProfessor Dario Alessi, University of Dundee
  • £145,600 over 3 years
  • Start date: October 2011
  • PhD studentship: H-1101

Changes in the Fbxo7 gene are linked to early onset forms of Parkinson's. So understanding what Fbxo7 does will help us understand why nerve cells die and help us develop better treatments for Parkinson's.

Understanding the role of the Fbxo7 gene in Parkinson's - research project summary (PDF,155KB)


Linking alpha-synuclein to Parkinson's

  • Dr Maria SpillantiniProfessor Maria Grazia Spillantini, University of Cambridge
  • £127,997 over 2 years
  • Start date: October 2011
  • Project grant: G-1102

Maria's project is investigating what the protein alpha-synuclein does inside nerve cells. Alpha-synuclein may be the key to Parkinson's because it forms sticky clumps that clog up the cells affected in people with the condition.

Linking alpha-synuclein to Parkinson's - research project summary (PDF, 170KB)


Targeting brain rhythms to find better treatments for Parkinson's

  • Dr Ian StanfordDr Ian Stanford, Aston University
  • £177,578 over 3 years
  • Start date: September 2011
  • Project grant: G-1008

Ian wants to know if zolpidem - a drug used for the treatment of insomnia - can reduce beta activity in the brain (which is abnormally high in people with Parkinson's). This could have exciting potential as a new treatment.

Targeting brain rhythms to find better treatments for Parkinson's - research project summary (PDF, 170KB)


Improving the way we replace the nerve cells lost in Parkinson's

  • Professor Anne RosserProfessor Anne Rosser, Cardiff University
  • £184,787 over 3 years
  • Start date: August 2011
  • Project grant: G-1105

Stem cell transplants have great potential as a future cure for Parkinson's - but there are still lots of challenges. Anne aims to find ways to help transplanted nerve cells survive and work properly once they're inside the Parkinson's brain.

Improving the way we replace the nerve cells lost in Parkinson's - research project summary (PDF, 168KB)


What is the link between Gaucher's disease and Parkinson's?

  • Professor Anthony SchapiraProfessor Anthony Schapira, Institute of Neurology, London
  • £333,229 over 3 years
  • Start date: July 2011
  • Project grant: G-1104

People who have a genetic condition called Gaucher's disease are more likely to develop Parkinson's. Anthony wants to know why and will investigate the genetics involved in both conditions.

What is the link between Gaucher's disease and Parkinson's? - research project summary (PDF, 100KB)


The development of Parkinson's in the brain

  • Dr Roger BarkerDr Roger Barker, University of Cambridge
  • £247,868 over 3 years
  • Start date: June 2011
  • Project grant: G-1011

Roger's project will study how the death of nerve cells spreads from one part of the brain to another in Parkinson's. Hopefully this will help identify ways to prevent it and halt the progression of the condition.

The development of Parkinson's in the brain - research project summary (PDF, 165KB)

How you can help

We are closer than ever to finding a cure, but we need your help.

Help fund our vital research

All our research is totally dependent on voluntary donations.